Scholarlink

Background <p>Relebactam is a new inhibitor of class A and class C β-lactamases. The FDA has approved combining IMI/CS/REL to treat some infectious diseases. This study systematically reviews the efficacy and safety of IMI/CS/REL based on existing clinical trials so as to provide a reference for follow-up research.</p> Methods <p>Researchers comprehensively searched PubMed, Embase, Cochrane Library, and ClinicalTrials.gov for randomised controlled trials published up to Mar 28, 2025, with “Imipenem/Cilastatin/Relebactam” or “IMI/CS/REL” as keywords, and screened the results according to the proposed exclusion and inclusion criteria. Data extraction was performed on the included randomized controlled trials (RCTs), while the day 28/30 all-cause mortality, clinical response rate, microbiological response rate, the adverse event response rate and drug-related adverse reaction rate were evaluated using R (4.4.3). The evaluation results were expressed in terms of relative risk with 95% confidence limit (RR, 95%CI).</p> Results <p>Six RCTs (1606 subjects) were involved in this meta-analysis. The meta-analysis showed no significant differences between IMI/CS/REL and comparators in day 28/30 all-cause mortality (RR = 0.82, 95% CI 0.39–1.72, <i>P</i> = 0.10), in clinical response rate during the early follow-up period (EFU) (RR = 1.02, 95%CI 0.96–1.08, <i>P</i> = 0.67) and in microbiological response at EFU (RR = 1.02, 95%CI 0.95–1.09, <i>P</i> = 0.76). The adverse events (AEs) rate also showed no statistical difference in each study’s arms (RR = 1.02, 95%CI 0.95–1.08, <i>P</i> = 0.87).</p> Conclusions <p>IMI/CS/REL demonstrates a non-inferior efficacy and safety profile compared to standard comparators in treating carbapenem-susceptible or carbapenem-resistant pathogens. Nevertheless, more robust clinical evidence—especially in resistant, polymicrobial, and pathogen-defined infections—is needed to fully establish its role in real-world practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of imipenem/cilastatin/relebactam (IMI/CS/REL): a meta-analysis of randomized controlled clinical trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月26日

查看全文
  • Wenjuan Lei,
  • Yan Duan,
  • Mingyan Xin,
  • Min Tian,
  • Jia Xu

摘要

Background

Relebactam is a new inhibitor of class A and class C β-lactamases. The FDA has approved combining IMI/CS/REL to treat some infectious diseases. This study systematically reviews the efficacy and safety of IMI/CS/REL based on existing clinical trials so as to provide a reference for follow-up research.

Methods

Researchers comprehensively searched PubMed, Embase, Cochrane Library, and ClinicalTrials.gov for randomised controlled trials published up to Mar 28, 2025, with “Imipenem/Cilastatin/Relebactam” or “IMI/CS/REL” as keywords, and screened the results according to the proposed exclusion and inclusion criteria. Data extraction was performed on the included randomized controlled trials (RCTs), while the day 28/30 all-cause mortality, clinical response rate, microbiological response rate, the adverse event response rate and drug-related adverse reaction rate were evaluated using R (4.4.3). The evaluation results were expressed in terms of relative risk with 95% confidence limit (RR, 95%CI).

Results

Six RCTs (1606 subjects) were involved in this meta-analysis. The meta-analysis showed no significant differences between IMI/CS/REL and comparators in day 28/30 all-cause mortality (RR = 0.82, 95% CI 0.39–1.72, P = 0.10), in clinical response rate during the early follow-up period (EFU) (RR = 1.02, 95%CI 0.96–1.08, P = 0.67) and in microbiological response at EFU (RR = 1.02, 95%CI 0.95–1.09, P = 0.76). The adverse events (AEs) rate also showed no statistical difference in each study’s arms (RR = 1.02, 95%CI 0.95–1.08, P = 0.87).

Conclusions

IMI/CS/REL demonstrates a non-inferior efficacy and safety profile compared to standard comparators in treating carbapenem-susceptible or carbapenem-resistant pathogens. Nevertheless, more robust clinical evidence—especially in resistant, polymicrobial, and pathogen-defined infections—is needed to fully establish its role in real-world practice.